Compare NTIC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | MAIA |
|---|---|---|
| Founded | 1970 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 79.0M |
| IPO Year | 1996 | 2022 |
| Metric | NTIC | MAIA |
|---|---|---|
| Price | $8.10 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 582.0K |
| Earning Date | 04-09-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $84,234,474.00 | N/A |
| Revenue This Year | $12.49 | N/A |
| Revenue Next Year | $7.64 | N/A |
| P/E Ratio | $413.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.14 | $0.87 |
| 52 Week High | $10.03 | $3.19 |
| Indicator | NTIC | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 56.15 |
| Support Level | $7.85 | $1.24 |
| Resistance Level | $8.53 | $1.46 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 10.65 | 68.42 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.